U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07321613) titled 'Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients' on Dec. 23, 2025.
Brief Summary: This is a multicenter, retrospective cohort study that aims to evaluate the efficacy and safety of a triple-drug cocktail (TCC), consisting of Thalidomide, Carmofur, and Compound Mylabris Capsules (CMC), in combination with conventional Transarterial Chemoembolization (TACE) for the treatment of patients with unresectable Hepatocellular Carcinoma (HCC).
Study Start Date: May 01, 2023
Study Type: OBSERVATIONAL
Condition:
Hepatocellular Cancer (HCC)
Intervention:
DRUG: Thalidomide (50mg)
Thalidomide tablets ...